Q-omics provides the consensus-scored TUG1 profile across patient tissues and cancer cell-line models. TUG1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TUG1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TUG1 RNA expression shows 21,019 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TUG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUG1 survival associations across molecular data types. TUG1 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUG1 RNA expression–survival associations across cancer types. High TUG1 expression shows unfavorable associations in ACC, LIHC, UVM, PAAD and HNSC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TUG1 RNA expression.
This table summarizes TUG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TUG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUG1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUSC, BLCA and CHOL. The HNSC box plot shows higher TUG1 RNA expression in tumor versus normal tissue (log2 FC = +1.161, t-test p < 0.001).
This table shows molecular features associated with TUG1 in patient tissues and cancer cell lines. In patient samples, TUG1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and NCI60_ALL.
